Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, February 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 first quarter financial results and to provide a business update.
Related news for (VERU)
- Veru to Participate in the Virtual BTIG Obesity Health Forum
- Biotech Today: From Sustainable Biomaterials to First-in-Class Therapies
- Today’s Top Performers: MoBot’s Market Review 05/28/25 07:00 AM
- Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
- Today’s Top Performers: MoBot’s Market Review 05/28/25 06:00 AM